Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of sorafenib tosylate when given
together with riluzole in treating patients with solid tumors or melanoma that has spread to
other places in the body and usually cannot be cured or controlled with treatment. Riluzole
may stop or slow the growth of tumor cells. Sorafenib tosylate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving riluzole together with
sorafenib tosylate may kill more tumor cells.